Cargando…
Do investors value the FDA orphan drug designation?
BACKGROUND: The Orphan Drug Act is an important piece of legislation that uses financial incentives to encourage the development of drugs that treat rare diseases. This analysis studies the effects of a portion of the Orphan Drug Act, the orphan drug designation. Specifically, it studies the value t...
Autor principal: | Miller, Kathleen L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477091/ https://www.ncbi.nlm.nih.gov/pubmed/28629392 http://dx.doi.org/10.1186/s13023-017-0665-6 |
Ejemplares similares
-
FDA orphan drug designations for lysosomal storage disorders – a cross-sectional analysis
por: Garbade, Sven F., et al.
Publicado: (2020) -
Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases
por: Miller, Kathleen L., et al.
Publicado: (2021) -
The drug development pipeline for glioblastoma—A cross sectional assessment of the FDA Orphan Drug Product designation database
por: Johann, Pascal, et al.
Publicado: (2021) -
A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act
por: Fermaglich, Lewis J., et al.
Publicado: (2023) -
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
por: Miller, Kathleen L., et al.
Publicado: (2020)